Paclitaxel

For research use only.

Catalog No.S1150 Synonyms: NSC 125973, PTX, Taxol, Onxal

149 publications

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 270 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Paclitaxel has been cited by 149 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NF7rfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv0TWM2OD1yLkCwNFI5PyEQvF2= MnHLV2FPT0WU
LC-2-ad NWH1XJVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;vVIp{UUN3ME2wMlAxODNzNzFOwG0> MUDTRW5ITVJ?
RL95-2 NHrYdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWyRnVGUUN3ME2wMlAxODZ4ODFOwG0> MmOxV2FPT0WU
MZ1-PC MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXaTWM2OD1yLkCwNFczQSEQvF2= NH3ESoJUSU6JRWK=
TE-8 NFrr[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHDUY9KSzVyPUCuNFAyOTdizszN Mn7xV2FPT0WU
SW954 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi4OlJKSzVyPUCuNFAyOTlizszN NFLGeFBUSU6JRWK=
TE-11 M{H4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMECxNlMh|ryP M13Pd3NCVkeHUh?=
PSN1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnMfpBKSzVyPUCuNFAyOyEQvF2= NYL0fYhUW0GQR1XS
MOLT-4 NULK[2RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LWd2lEPTB;MD6wNFE1QSEQvF2= NXLBZmpnW0GQR1XS
697 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\VcGJ5UUN3ME2wMlAxOTVizszN NH3SOpJUSU6JRWK=
ETK-1 NGLSVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nGcWlEPTB;MD6wNFE2OiEQvF2= NWi3WG11W0GQR1XS
TE-10 M{jtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEftV2VKSzVyPUCuNFAyPTRizszN NXTJT5pWW0GQR1XS
HUTU-80 M4PMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;p[GdKSzVyPUCuNFAyPjhizszN M1TQS3NCVkeHUh?=
NTERA-S-cl-D1 NYXMfHBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj1TWM2OD1yLkCwNlA6KM7:TR?= M1LtOnNCVkeHUh?=
MFH-ino M37V[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzUdGZiUUN3ME2wMlAxOjZ6IN88US=> Mnj0V2FPT0WU
IA-LM NH\QRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjLdpBKSzVyPUCuNFAzQCEQvF2= MWTTRW5ITVJ?
MC116 NFq5S2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PLNWlEPTB;MD6wNFI5QSEQvF2= MlnNV2FPT0WU
RKO NIjkWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLufFdsUUN3ME2wMlAxOjl6IN88US=> M2HhZ3NCVkeHUh?=
MRK-nu-1 NI\qRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMECyPVkh|ryP NVfqS4ZkW0GQR1XS
VA-ES-BJ NYnm[3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLsTFNKSzVyPUCuNFA{KM7:TR?= MVLTRW5ITVJ?
KALS-1 M3nZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnnTWM2OD1yLkCwN|A5KM7:TR?= NHTl[pFUSU6JRWK=
BB30-HNC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPWUY1jUUN3ME2wMlAxOzF2IN88US=> M3vESHNCVkeHUh?=
ACN NVnKPIg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\0T3VRUUN3ME2wMlAxOzF4IN88US=> NFfPXGxUSU6JRWK=
TE-9 NILxT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXVO|FiUUN3ME2wMlAxOzJ4IN88US=> M1fi[nNCVkeHUh?=
SIG-M5 M1XPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMECzNlch|ryP NV\VcopiW0GQR1XS
no-10 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e3UGlEPTB;MD6wNFM3OiEQvF2= M2TrO3NCVkeHUh?=
EW-1 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[4bmpKSzVyPUCuNFA{PzFizszN NUPGXlV[W0GQR1XS
SK-LMS-1 NGi5SlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPNTWM2OD1yLkCwOFAyKM7:TR?= NUPseZI1W0GQR1XS
GT3TKB MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfwcYRKSzVyPUCuNFA1OzRizszN MXPTRW5ITVJ?
ES4 NELCbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHY[WFKSzVyPUCuNFA1PDlizszN M4ewXHNCVkeHUh?=
IMR-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nSbmlEPTB;MD6wNFQ2KM7:TR?= MnfVV2FPT0WU
NCI-H1648 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;QTWM2OD1yLkCwOFY6KM7:TR?= M3\x[nNCVkeHUh?=
MV-4-11 NFLRZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfEV4ptUUN3ME2wMlAxPDd3IN88US=> NI\ldFRUSU6JRWK=
SK-UT-1 NUj2TWFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L4cmlEPTB;MD6wNFQ5KM7:TR?= MlXvV2FPT0WU
NB13 MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrHZlU{UUN3ME2wMlAxPDlzIN88US=> MkHkV2FPT0WU
DJM-1 NXrZdHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILYUXBKSzVyPUCuNFA2OyEQvF2= MkLGV2FPT0WU
ES8 M1;w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjKRnBKSzVyPUCuNFA2OzhizszN NGPVO4FUSU6JRWK=
TE-6 NH3zO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMEC1O{DPxE1? NFm1TmNUSU6JRWK=
KS-1 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEC1PFIh|ryP NI\aRmdUSU6JRWK=
TE-1 M3rZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fiUmlEPTB;MD6wNFYxPiEQvF2= M4jHb3NCVkeHUh?=
ATN-1 NF[xcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMEC2NFkh|ryP Ml3sV2FPT0WU
A4-Fuk MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXCdmJEUUN3ME2wMlAxPjFzIN88US=> M1PSbnNCVkeHUh?=
ALL-PO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rZdWlEPTB;MD6wNFY{KM7:TR?= NGO2c|dUSU6JRWK=
BE-13 NHzHRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrrWYY6UUN3ME2wMlAxPjN4IN88US=> NIXPOnFUSU6JRWK=
KM12 MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEC2N|ch|ryP NYG2UYh1W0GQR1XS
NOS-1 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\zdGNKSzVyPUCuNFA3PSEQvF2= NYK2RVR[W0GQR1XS
SW962 NUnmeYZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEC2OlIh|ryP NYPr[VFMW0GQR1XS
OCUB-M NHPPdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTXUI5KSzVyPUCuNFA3PjJizszN NFzjSYxUSU6JRWK=
NCI-H510A NXnZUIt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMEC2OlUh|ryP NF\z[IZUSU6JRWK=
EW-16 M1KxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf1coJKSzVyPUCuNFA3QTRizszN NXHkZY03W0GQR1XS
KGN Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PhWGlEPTB;MD6wNFcyOiEQvF2= NV\5SldNW0GQR1XS
LS-411N MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXmNnUxUUN3ME2wMlAxPzF5IN88US=> M2LIenNCVkeHUh?=
Becker M3XIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC5fWJKSzVyPUCuNFA4OiEQvF2= Mm\DV2FPT0WU
HC-1 NY\j[Yx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfrVHNHUUN3ME2wMlAxPzJzIN88US=> M3n0VHNCVkeHUh?=
CESS NF3ET|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDDem9lUUN3ME2wMlAxPzN5IN88US=> Ml\ZV2FPT0WU
KURAMOCHI NVzSNmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17aN2lEPTB;MD6wNFc1QCEQvF2= MWTTRW5ITVJ?
TGBC24TKB M{XTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG3c2R[UUN3ME2wMlAxPzV{IN88US=> NGnjOmtUSU6JRWK=
SW982 M1z4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEC3OlYh|ryP NV;3ZotOW0GQR1XS
HCE-4 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnDTWM2OD1yLkCwO|Y4KM7:TR?= NYL5PI1qW0GQR1XS
LOUCY MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS0TWM2OD1yLkCwO|c2KM7:TR?= M3;6RXNCVkeHUh?=
8-MG-BA NU\EeoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXafoxKSzVyPUCuNFA4QTZizszN M2nwTnNCVkeHUh?=
HT-144 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr6flI3UUN3ME2wMlAxQCEQvF2= NH7Tb2hUSU6JRWK=
LXF-289 NXL3ZlBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3l[oNKSzVyPUCuNFA5OThizszN M{S0XXNCVkeHUh?=
RS4-11 NETORnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEC4N|Yh|ryP NEjnWIpUSU6JRWK=
DEL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;0PGlEPTB;MD6wNFg1PSEQvF2= MXfTRW5ITVJ?
OCI-AML2 M2Xt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMEC4OVIh|ryP MVzTRW5ITVJ?
CCRF-CEM NX7lOnlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnwcWVKSzVyPUCuNFA5PzFizszN MmOyV2FPT0WU
A388 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorNTWM2OD1yLkCwPFc1KM7:TR?= Mn75V2FPT0WU
KNS-42 M33LNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMEC4PVEh|ryP M{S1[3NCVkeHUh?=
OVCAR-4 NU\nTJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfqbW5KSzVyPUCuNFA6ODRizszN NE\xTppUSU6JRWK=
NCI-H1355 NGm5OVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD6S2JCUUN3ME2wMlAxQTF2IN88US=> MYDTRW5ITVJ?
BL-70 NVjaXVlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEC5N{DPxE1? M3XWR3NCVkeHUh?=
BL-41 M1HS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLPTWM2OD1yLkCwPVM1KM7:TR?= NVXreWZOW0GQR1XS
A101D NYrpOI4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVyzXZN2UUN3ME2wMlAxQTZizszN M{fubXNCVkeHUh?=
HL-60 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPRZpZjUUN3ME2wMlAxQTZ4IN88US=> NUjrfFBpW0GQR1XS
COR-L279 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISxUWhKSzVyPUCuNFA6QTlizszN M2fKTHNCVkeHUh?=
NCI-SNU-16 NVvCdYY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXMXFNuUUN3ME2wMlAyODB6IN88US=> MYPTRW5ITVJ?
Calu-6 NXXXd2hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW5OpVKSzVyPUCuNFExOTJizszN NXqxb4lWW0GQR1XS
SR NFT4c|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEGwNlYh|ryP MVzTRW5ITVJ?
QIMR-WIL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PMT2lEPTB;MD6wNVA{OyEQvF2= M3XkPHNCVkeHUh?=
LB647-SCLC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXYclRKSzVyPUCuNFExPTFizszN NVjaXIdpW0GQR1XS
RPMI-8226 M4P1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLUTWM2OD1yLkCxNVAzKM7:TR?= MX7TRW5ITVJ?
SK-PN-DW M3r6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEGxNVIh|ryP NWjyPXd1W0GQR1XS
SF268 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXYbYtKSzVyPUCuNFEyPTFizszN M3TOfXNCVkeHUh?=
HD-MY-Z NX\IS4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK3N4VpUUN3ME2wMlAyOTZ|IN88US=> MnXDV2FPT0WU
DOHH-2 M4nGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\rTWM2OD1yLkCxNlA{KM7:TR?= MYLTRW5ITVJ?
SCC-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnuTVY6UUN3ME2wMlAyOjB2IN88US=> MYDTRW5ITVJ?
ST486 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEGyNFQh|ryP NGm1SoJUSU6JRWK=
NALM-6 M12wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX3NpJ3UUN3ME2wMlAyOjF2IN88US=> NX\E[IRVW0GQR1XS
NCI-H1436 NHvSZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW4TWM2OD1yLkCxNlMyKM7:TR?= NUT0e2xwW0GQR1XS
KE-37 M1;kPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHOcoQyUUN3ME2wMlAyOjN2IN88US=> NWfMdVlxW0GQR1XS
RPMI-8402 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMEGyOVYh|ryP Mlm3V2FPT0WU
RXF393 NF:1Z4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEGyOVch|ryP M1rKWHNCVkeHUh?=
KARPAS-45 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu1e5dKSzVyPUCuNFEzPyEQvF2= NVPjOY5xW0GQR1XS
HOP-62 M4jQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly0TWM2OD1yLkCxNlc3KM7:TR?= NHHpT4hUSU6JRWK=
ES1 NF7zcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPcmlEPTB;MD6wNVI5QCEQvF2= NY[xZ|J3W0GQR1XS
L-363 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\5PJVsUUN3ME2wMlAyOzVzIN88US=> Mny3V2FPT0WU
GI-1 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHlTWM2OD1yLkCxN|c{KM7:TR?= NGHT[oNUSU6JRWK=
CTV-1 NWf2UXZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C1V2lEPTB;MD6wNVQ4QCEQvF2= MXvTRW5ITVJ?
TE-5 NH30NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEG0PVYh|ryP M4H5[HNCVkeHUh?=
SNU-C2B M{Swbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPZO3BYUUN3ME2wMlAyPDl4IN88US=> MUjTRW5ITVJ?
K-562 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfVNYtKSzVyPUCuNFE2OTZizszN MWfTRW5ITVJ?
SNB75 NUTDSFV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEG1OEDPxE1? NGPCRmZUSU6JRWK=
MOLT-13 NICwSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMEG2N|ch|ryP MojkV2FPT0WU
LS-123 NHHEb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEG2OlQh|ryP NWmyN4trW0GQR1XS
NCI-SNU-5 NFj1WJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljmTWM2OD1yLkCxO|AyKM7:TR?= M{fHdHNCVkeHUh?=
Daudi MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3FSXhKSzVyPUCuNFE4ODhizszN MlzLV2FPT0WU
A253 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7hTWM2OD1yLkCxO|M5KM7:TR?= NW[zdWtYW0GQR1XS
TGBC1TKB NV3LRmdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDzTWM2OD1yLkCxO|UzKM7:TR?= NWTofVFwW0GQR1XS
SJSA-1 NWrqXXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\sdGlEPTB;MD6wNVc3PyEQvF2= MYTTRW5ITVJ?
NCCIT NHT5dW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\6TWM2OD1yLkCxO|Y6KM7:TR?= MXTTRW5ITVJ?
NCI-H69 NGHMWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnB[HJKSzVyPUCuNFE4PzhizszN NFrMUnBUSU6JRWK=
SH-4 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH1TWM2OD1yLkCxPFk2KM7:TR?= MoLHV2FPT0WU
HCC1187 M3PtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEG5NlQh|ryP M1ixPXNCVkeHUh?=
HCC1599 NIXyblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2focmlEPTB;MD6wNlAzKM7:TR?= MVPTRW5ITVJ?
ONS-76 M3qyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LYU2lEPTB;MD6wNlA{PiEQvF2= NYnIb5BRW0GQR1XS
KU812 NVX3U2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NICyZmtKSzVyPUCuNFIxOzlizszN NXLoWVJYW0GQR1XS
ML-2 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G5N2lEPTB;MD6wNlA1PyEQvF2= M{PMenNCVkeHUh?=
HCE-T NHf5XndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TZSWlEPTB;MD6wNlA6OiEQvF2= NX34PZZ6W0GQR1XS
NCI-H446 NXvy[3R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XGWmlEPTB;MD6wNlEyOiEQvF2= MmPHV2FPT0WU
RPMI-6666 NFHoc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTUTmdrUUN3ME2wMlAzOTR7IN88US=> M3HOZXNCVkeHUh?=
MOLT-16 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWezd2dwUUN3ME2wMlAzOTV|IN88US=> NYfKcZY2W0GQR1XS
JiyoyeP-2003 NWPJ[Wg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHiOFk2UUN3ME2wMlAzOTd4IN88US=> MULTRW5ITVJ?
MHH-PREB-1 NWPz[ZJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nyemlEPTB;MD6wNlE6OSEQvF2= NVLCU4pIW0GQR1XS
MC-CAR Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M173NmlEPTB;MD6wNlMzPiEQvF2= NEPjVpVUSU6JRWK=
BC-3 NYDpeGdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;jTWM2OD1yLkCyN|Q1KM7:TR?= NX\kcnA4W0GQR1XS
KINGS-1 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMEKzOVUh|ryP MmPjV2FPT0WU
PF-382 M3jPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLNXYg3UUN3ME2wMlAzOzd6IN88US=> NVLEPVJiW0GQR1XS
J-RT3-T3-5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLGc5lOUUN3ME2wMlAzOzh|IN88US=> MXnTRW5ITVJ?
SF539 M4iwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLKSpRlUUN3ME2wMlAzPDBzIN88US=> NWrUPHYzW0GQR1XS
LB831-BLC MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrFVohKSzVyPUCuNFI1QDVizszN NHTjXJJUSU6JRWK=
DMS-114 NUn3SGRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTY[odWUUN3ME2wMlAzPTB{IN88US=> NGfUbmFUSU6JRWK=
LB1047-RCC NIHvWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLRSnUzUUN3ME2wMlAzPTFizszN NUHTfpRFW0GQR1XS
LB771-HNC MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEK1N|Qh|ryP NFrjOHdUSU6JRWK=
BB65-RCC M3fXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq3TWM2OD1yLkCyOVM1KM7:TR?= NIm2UpFUSU6JRWK=
BV-173 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMEK1OVQh|ryP MXLTRW5ITVJ?
ARH-77 NYTycZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;ZZphKSzVyPUCuNFI3ODFizszN NGTzVHZUSU6JRWK=
IST-MEL1 NGHsdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjhPFdKSzVyPUCuNFI3OjNizszN M1S5O3NCVkeHUh?=
NB1 NEPZc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPBTWM2OD1yLkCyOlg4KM7:TR?= M13oeXNCVkeHUh?=
EoL-1-cell NXmyPWtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH5bmVKSzVyPUCuNFI3QDhizszN NYnoblZHW0GQR1XS
KY821 MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMEK2PVch|ryP Mkn1V2FPT0WU
CMK NXLyeotWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMEK3N|Qh|ryP MYPTRW5ITVJ?
NCI-H2126 M1LUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPYTWNPUUN3ME2wMlAzPzZ6IN88US=> Ml3YV2FPT0WU
NCI-H526 NFHwbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMEK4PVEh|ryP NYTkSlhrW0GQR1XS
COLO-684 NVTETWU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\ITWM2OD1yLkCyPVA5KM7:TR?= NV7MeWpLW0GQR1XS
NCI-H747 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rTPGlEPTB;MD6wNlk{OyEQvF2= MYjTRW5ITVJ?
JAR MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMEK5OFYh|ryP M4LpXnNCVkeHUh?=
MEG-01 M2\Ed2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEK5O|gh|ryP Ml3PV2FPT0WU
MONO-MAC-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jVd2lEPTB;MD6wN|AzOyEQvF2= MV;TRW5ITVJ?
IST-SL1 NIP4UJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEOwOFIh|ryP NHTmd|lUSU6JRWK=
CPC-N Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:xSGlEPTB;MD6wN|A4QSEQvF2= MYLTRW5ITVJ?
NCI-H1963 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTITWM2OD1yLkCzNVMyKM7:TR?= NIDTOnJUSU6JRWK=
K052 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PSO2lEPTB;MD6wN|I1PyEQvF2= MWrTRW5ITVJ?
KM-H2 M4HlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEOzNFch|ryP MVfTRW5ITVJ?
TE-12 M4XMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn35TWM2OD1yLkCzN|A6KM7:TR?= NYrDNJF4W0GQR1XS
TK10 M4fDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PDfWlEPTB;MD6wN|M2PiEQvF2= NX61NYx6W0GQR1XS
NMC-G1 NHTUXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEO0OVIh|ryP MULTRW5ITVJ?
no-11 MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEO0O|gh|ryP M1WxRXNCVkeHUh?=
NCI-H524 NX7jc4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO2[oRKSzVyPUCuNFM2OjlizszN M3TWNXNCVkeHUh?=
MHH-CALL-2 NHn0boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHxTYo{UUN3ME2wMlA{PTZ{IN88US=> NVXkRXVSW0GQR1XS
GB-1 M1;uT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jLTmlEPTB;MD6wN|Yh|ryP MmjHV2FPT0WU
OPM-2 NF;FbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLZbotkUUN3ME2wMlA{Pjd|IN88US=> NUXrZlhZW0GQR1XS
RH-1 NH3tdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTVTYJmUUN3ME2wMlA{QDF7IN88US=> NEnNW41USU6JRWK=
NCI-H64 NUT2NpJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\hZWNvUUN3ME2wMlA{QDV5IN88US=> MYHTRW5ITVJ?
EVSA-T MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LwUGlEPTB;MD6wN|kzOyEQvF2= MXTTRW5ITVJ?
KARPAS-299 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;yV4ZKSzVyPUCuNFM6QCEQvF2= M3jxeXNCVkeHUh?=
MZ7-mel NIHzUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMESwOEDPxE1? NV\Wbnk5W0GQR1XS
LB373-MEL-D M{XicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojYTWM2OD1yLkC0NVA2KM7:TR?= M4HSWHNCVkeHUh?=
HEL NXHNU4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGxTmlKSzVyPUCuNFQyPCEQvF2= NXLqcYNtW0GQR1XS
SW872 NGq3V3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLrVXZHUUN3ME2wMlA1OjFizszN MkK0V2FPT0WU
DU-4475 NUP6bJNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPqTWM2OD1yLkC0NlQ1KM7:TR?= MXXTRW5ITVJ?
IST-SL2 NY\0PWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXWTWM2OD1yLkC0Nlc2KM7:TR?= MkfpV2FPT0WU
NCI-H82 NV3QWFAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMESzNFch|ryP M4C0RnNCVkeHUh?=
LC4-1 NE\IT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrNV4dsUUN3ME2wMlA1OzVzIN88US=> MlvQV2FPT0WU
HDLM-2 NIDUbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTqbnBRUUN3ME2wMlA1Ozl{IN88US=> Mm[xV2FPT0WU
MMAC-SF NGXEcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMES1N|Qh|ryP NVq1VZp[W0GQR1XS
L-540 NFnSZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7qfGhKSzVyPUCuNFQ3OzlizszN MVrTRW5ITVJ?
MZ2-MEL MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDpcpN7UUN3ME2wMlA1PzR{IN88US=> M2[y[XNCVkeHUh?=
LU-134-A NFvOR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPGTYdKSzVyPUCuNFQ4PzNizszN MX;TRW5ITVJ?
UACC-257 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OwfmlEPTB;MD6wOFg1QSEQvF2= NGfiUZBUSU6JRWK=
NCI-H1581 NEXZO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7kXllKSzVyPUCuNFQ6PTNizszN MWHTRW5ITVJ?
NB17 M1TOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X6SmlEPTB;MD6wOFk4QSEQvF2= MXjTRW5ITVJ?
SBC-1 NHTNVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX64dIhVUUN3ME2wMlA2ODR{IN88US=> NF;0d5BUSU6JRWK=
TALL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH3[|c{UUN3ME2wMlA2ODR3IN88US=> MmLkV2FPT0WU
NCI-H1304 NVHCWVNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnHZodpUUN3ME2wMlA2OjB6IN88US=> MmnHV2FPT0WU
NEC8 NUnOW2twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;s[XNJUUN3ME2wMlA2Ojh4IN88US=> Mn3KV2FPT0WU
CAL-148 NGK0V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j1ZWlEPTB;MD6wOVQ{QSEQvF2= MXzTRW5ITVJ?
CGTH-W-1 M4HtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEW0OFkh|ryP MVnTRW5ITVJ?
NCI-H889 NHTQ[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMEW1PVIh|ryP Mof1V2FPT0WU
GR-ST NXW1O4F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13Zd2lEPTB;MD6wOVYzOSEQvF2= M2XESXNCVkeHUh?=
KARPAS-422 NGLvfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPUUVlKSzVyPUCuNFU3PSEQvF2= NF3xT5dUSU6JRWK=
RPMI-8866 NVHDeI9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEW3NVIh|ryP NWm4c4xDW0GQR1XS
SCLC-21H Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrwbGNwUUN3ME2wMlA2QDh2IN88US=> NWrUWYRpW0GQR1XS
COR-L88 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEW5Nlch|ryP Ml\HV2FPT0WU
LU-139 NHjZXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXGNmFKSzVyPUCuNFU6QDZizszN MXjTRW5ITVJ?
SF126 NEKxcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwME[xN|Mh|ryP MV\TRW5ITVJ?
NCI-H1882 NVfVfWwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHqXnFKSzVyPUCuNFY1OjRizszN M3[0OHNCVkeHUh?=
EW-24 M33I[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ocFdKSzVyPUCuNFY1QDNizszN MXXTRW5ITVJ?
CP67-MEL M3PoUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnxTWM2OD1yLkC2PFEh|ryP M1S5SHNCVkeHUh?=
DG-75 M2TtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nVSWlEPTB;MD6wOlg6QSEQvF2= M{XldHNCVkeHUh?=
LOXIMVI NE[2fI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTDWGJKSzVyPUCuNFcxOjhizszN NGDZU|lUSU6JRWK=
HH MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljkTWM2OD1yLkC3NVU4KM7:TR?= MXHTRW5ITVJ?
K5 NVH4U49kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPIT4lKSzVyPUCuNFczOjZizszN M1XCfnNCVkeHUh?=
EC-GI-10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DIXWlEPTB;MD6wO|I2PyEQvF2= M4fPPHNCVkeHUh?=
SK-N-DZ NX[1dXRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XmcWlEPTB;MD6wO|MxPyEQvF2= NWXYVJZyW0GQR1XS
A3-KAW MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;STWM2OD1yLkC3N|UyKM7:TR?= NF7tTVNUSU6JRWK=
MLMA Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEe0OlUh|ryP M{LMdnNCVkeHUh?=
LB996-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDPTWM2OD1yLkC3O|A4KM7:TR?= MoXXV2FPT0WU
OS-RC-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jXR2lEPTB;MD6wO|c1QCEQvF2= NETifm1USU6JRWK=
CTB-1 NVLje3V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjjOVJKSzVyPUCuNFc5OSEQvF2= Mni3V2FPT0WU
IST-MES1 NIDs[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrL[4RCUUN3ME2wMlA4QTF{IN88US=> NEXTdlVUSU6JRWK=
LS-1034 NXXtNYxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMEiwN|Uh|ryP M2LOZnNCVkeHUh?=
HT M{\Sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjxTWM2OD1yLkC4NFg3KM7:TR?= MkjKV2FPT0WU
NCI-H2141 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEixJO69VQ>? NHvsWHFUSU6JRWK=
LB2518-MEL NGe0ZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPtTWM2OD1yLkC4NVQyKM7:TR?= M{fZTXNCVkeHUh?=
GI-ME-N NXu2WWplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\5W5RKSzVyPUCuNFg1PTJizszN NFrsfGhUSU6JRWK=
TGW MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P0bWlEPTB;MD6wPFYxPyEQvF2= NX;INpQ4W0GQR1XS
SK-NEP-1 NV7MfFhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTKNZpKSzVyPUCuNFg3PDFizszN NHjxb|hUSU6JRWK=
NOMO-1 NGPYSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMEmyO|Uh|ryP NWq3NYFtW0GQR1XS
ES6 M4j4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEm1PFkh|ryP NV3IbVVZW0GQR1XS
NCI-H209 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPSTWM2OD1yLkC5O|g3KM7:TR?= MoDQV2FPT0WU
GAK NETuNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Sx[mlEPTB;MD6xNFE3KM7:TR?= MlLSV2FPT0WU
BC-1 NV\4fXdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrLSG1RUUN3ME2wMlExOzZzIN88US=> NYTMUGYzW0GQR1XS
KLE NVi5PZl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMUC0OFMh|ryP NH\QRZRUSU6JRWK=
EW-3 M1jz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV62WZY1UUN3ME2wMlExQThizszN NFL4ZYNUSU6JRWK=
NKM-1 MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfOe|hNUUN3ME2wMlEyOSEQvF2= Mk\mV2FPT0WU
D-336MG Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TyUGlEPTB;MD6xNVI1PCEQvF2= M1v1SHNCVkeHUh?=
NB69 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMUGzNFEh|ryP NHzE[nlUSU6JRWK=
D-263MG M1LvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2ydYo1UUN3ME2wMlEyPzF{IN88US=> Mo\GV2FPT0WU
KP-N-YS M{DNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf3TWM2OD1yLkGyNlkyKM7:TR?= M2rsc3NCVkeHUh?=
NCI-H1155 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HHdGlEPTB;MD6xNlU2QCEQvF2= NYTMcWh4W0GQR1XS
BOKU M1;X[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2flNmlEPTB;MD6xNlU4QSEQvF2= NYS4W4hVW0GQR1XS
LAMA-84 NUnt[npQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXlRXZsUUN3ME2wMlEzQTlizszN NH7m[XZUSU6JRWK=
Raji Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD2fZFKSzVyPUCuNVMyOTdizszN M4j5UnNCVkeHUh?=
LU-65 M33GbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DscmlEPTB;MD6xN|MxPyEQvF2= M13EXnNCVkeHUh?=
NCI-H187 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXUTWM2OD1yLkGzPVI1KM7:TR?= MlTrV2FPT0WU
GCIY MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LpOWlEPTB;MD6xOFkxOSEQvF2= M3;oNnNCVkeHUh?=
NCI-H2107 M3nYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vCeGlEPTB;MD6xOVA5KM7:TR?= M3i0R3NCVkeHUh?=
NCI-H1522 M3\JVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j4WGlEPTB;MD6xOVI3PiEQvF2= MVfTRW5ITVJ?
NB6 NUTRd2VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j4[GlEPTB;MD6xOVYzOyEQvF2= NHG5W2FUSU6JRWK=
EM-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HIV2lEPTB;MD6xOVcxPiEQvF2= NETGVllUSU6JRWK=
HCC2218 NYO0cohsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXezOIViUUN3ME2wMlE2QThizszN NVizXVJ6W0GQR1XS
NCI-H748 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILrO|NKSzVyPUCuNVY{PzZizszN MVrTRW5ITVJ?
MS-1 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWyN|hKSzVyPUCuNVY2OzdizszN MkLIV2FPT0WU
NB5 M1vrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj6TWM2OD1yLkG2OVk4KM7:TR?= NXPlcFNZW0GQR1XS
OMC-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjydWc{UUN3ME2wMlE3Pjh6IN88US=> MmH3V2FPT0WU
NCI-H345 M3GyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDVWGRKSzVyPUCuNVY6OjhizszN M{ezRXNCVkeHUh?=
L-428 NWDlSII3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3QN40zUUN3ME2wMlE3QTR3IN88US=> MWDTRW5ITVJ?
SCH MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC2TWM2OD1yLkG4Olg2KM7:TR?= Mom2V2FPT0WU
NCI-H1417 M37RTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\PTWM2OD1yLkG5NlI4KM7:TR?= NH\WeJhUSU6JRWK=
COLO-320-HSR Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfOTWM2OD1yLkG5OVMzKM7:TR?= MXfTRW5ITVJ?
BT-474 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;Jb2lEPTB;MD6yNFg6OiEQvF2= MYPTRW5ITVJ?
GDM-1 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMkG5O|Eh|ryP MYTTRW5ITVJ?
NCI-H2196 M4HnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTuS2pKSzVyPUCuNlIzOzVizszN NUfZXm5nW0GQR1XS
KP-N-RT-BM-1 NFzjbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PPfmlEPTB;MD6yNlM1QSEQvF2= M{HaSXNCVkeHUh?=
KNS-81-FD NEDQXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3STWM2OD1yLkKyPVU5KM7:TR?= NWXiXI9qW0GQR1XS
COLO-668 MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHCTWM2OD1yLkKzOlc2KM7:TR?= NELweZhUSU6JRWK=
C2BBe1 M{jZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMk[3OFch|ryP M2j3fnNCVkeHUh?=
Ramos-2G6-4C10 M{O3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rsdmlEPTB;MD6yOlk2PCEQvF2= M3\iW3NCVkeHUh?=
CAS-1 M3PseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHlPHVyUUN3ME2wMlI4ODl4IN88US=> NULneGNpW0GQR1XS
GOTO MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDyUnJKSzVyPUCuNlc5QTRizszN MljzV2FPT0WU
LP-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz6TZBKSzVyPUCuNlgxPTdizszN NFrHdZVUSU6JRWK=
NCI-SNU-1 NYe2NGxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMkm0NlIh|ryP M{fPbXNCVkeHUh?=
EB-3 NVPsXVVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXlfVRFUUN3ME2wMlI6QTd7IN88US=> NWfC[WV{W0GQR1XS
MHH-NB-11 M4DFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TMO2lEPTB;MD6zNFQxOiEQvF2= MliwV2FPT0WU
SK-N-FI NYTa[ZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfvNpduUUN3ME2wMlMyPjl{IN88US=> M2XoeXNCVkeHUh?=
HCC2157 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH33PVJKSzVyPUCuN|M6OTNizszN MVTTRW5ITVJ?
SIMA M3zIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\IbHpKSzVyPUCuN|Q2QDFizszN Mn7uV2FPT0WU
MDA-MB-134-VI MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPVeIY{UUN3ME2wMlM3QTJ6IN88US=> NIrudG1USU6JRWK=
NCI-H1694 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojuTWM2OD1yLkO3JO69VQ>? MUHTRW5ITVJ?
EHEB M3TFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rjXGlEPTB;MD6zPVA5PSEQvF2= M4n5dHNCVkeHUh?=
U-266 NHjoc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzBWmQ3UUN3ME2wMlM6QDR4IN88US=> MYjTRW5ITVJ?
LC-1F MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\LZWlEPTB;MD60N|c3PSEQvF2= MXzTRW5ITVJ?
SHP-77 MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP4TWM2OD1yLkS3PFU2KM7:TR?= NHrHW4hUSU6JRWK=
LS-513 M{LRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwNEmzNFch|ryP Mn3MV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Water Insoluble
Ethanol '18 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973, PTX, Taxol, Onxal
Smiles CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)C4=CC=CC=C4)C5(O)CC(OC(=O)C(O)C(NC(=O)C6=CC=CC=C6)C7=CC=CC=C7)C(=C1C5(C)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04338399 Not yet recruiting Drug: Buparlisib & Paclitaxel Head and Neck Cancer Adlai Nortye Biopharma Co. Ltd. July 31 2020 Phase 3
NCT04251169 Not yet recruiting Drug: Pembrolizumab|Drug: Paclitaxel Metastatic Breast Cancer SOLTI Breast Cancer Research Group|Merck Sharp & Dohme Corp. July 15 2020 Phase 2
NCT04252768 Not yet recruiting Drug: Eftilagimod Alpha|Drug: Paclitaxel Metastatic Breast Cancer Immutep S.A. June 2020 Phase 1
NCT04374630 Not yet recruiting Drug: Paclitaxel|Drug: Afuresertib Platinum-resistant Ovarian Cancer Laekna Limited June 9 2020 Phase 2
NCT04354961 Not yet recruiting Drug: Almonertinib|Drug: Paclitaxel and carboplatin Pulmonary Adenosquamous Carcinoma Fujian Cancer Hospital|Jiangsu Hansoh Pharmaceutical Co. Ltd. June 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID